<DOC>
	<DOCNO>NCT02048358</DOCNO>
	<brief_summary>In first human study aim ass safety , pharmacokinetics pharmacodynamics 2B3-201 randomized , first human , double-blind , placebo- active comparator- control 3-way crossover study 18 healthy male subject ( part 1 ) . Furthermore , finding obtain part 1 extend confirm subsequent parallel open label study 18 healthy male 12 MS patient open label study methylprednisolone comparator 12 female volunteer ( part 2 ) .</brief_summary>
	<brief_title>Safety , Pharmacokinetics Pharmacodynamics Study With 2B3-201 Healthy Subjects Multiple Sclerosis ( MS ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Healthy subject Healthy male female subject , 18 45 year age , inclusive . Healthy status define absence evidence active chronic disease follow detailed medical surgical history , complete physical examination include vital sign , 12lead ECG , hematology , blood chemistry , urinalysis . Body mass index ( BMI ) 18 30 kg/m2 , inclusive , minimum weight 50 kg . Able participate willing give write informed consent comply study restriction . Relapsing MS patient Age : 18 65 year , men woman . Patients relapse multiple sclerosis ( RMS ) , define , acute exacerbation , opinion treat physician undergo 3 5 day course high dose methylprednisolone ; Patients Relapsing Remitting Multiple Sclerosis ( RRMS ) . Patients Secondary Progressive Multiple Sclerosis ( SPMS ) Patients clinically isolate syndrome ( CIS ) show dissemination lesion time ( DIT ) space ( DIS ) MRI scan accord 2010 McDonald criterion . Able participate willing comply study restriction . Understands sign write informed consent prior test protocol , include screen test evaluation consider part subject 's routine care . Healthy volunteer : Any subject pregnant breastfeeding . A urine pregnancy test perform female subject childbearing potential ( define &lt; 2 year last menstruation surgically sterile ) prior start study treatment . For female subject childbearing potential ( define &lt; 2 year last menstruation surgically sterile ) male subject surgically sterile female partner childbearing potential : absence effective , nonhormonal mean contraception ( intrauterine contraceptive device , barrier method contraception conjunction spermicidal gel ) contraindication . Not willing use doublebarrier contraception , duration study 3 month last dose . Positive test drug abuse screen predose . History alcohol consumption exceed 2 standard drink per day average ( 1 standard drink = 10 gram alcohol ) within 3 month screen . Alcohol consumption prohibit study confinement least 48 hour screen , dose , schedule visit . History symptoms significant disease include ( limited ) , neurological , psychiatric , endocrine , cardiovascular , respiratory , gastrointestinal , hepatic , renal disorder . Positive Hepatitis B surface antigen ( HBsAg ) , Hepatitis C antibody ( HCV Ab ) , human immunodeficiency virus antibody ( HIV Ab ) screening . Systolic blood pressure ( SBP ) great 140 mm Hg le 90 mm Hg , diastolic blood pressure ( DBP ) great 90 mm Hg le 50 mm Hg . Use medication ( prescription overthecounter [ OTC ] ) , vitamin , mineral , herbal , dietary supplement within 21 day study drug administration . Exceptions paracetamol ( 4 g/day ) . Use CYP3A4inhibiting drug , include quinine contain drink ( bitter lemon tonic water ) prohibit within 21 day study drug administration Subject use grapefruit , grapefruit juice , grapefruitcontaining product , Seville oranges , pomelocontaining product , within 14 day prior day 1 . Clinically significant abnormality , judge investigator , laboratory test result ( include hepatic renal panel , complete blood count , chemistry panel urinalysis ) . In case uncertain questionable result , test perform screen may repeat randomization confirm eligibility judge clinically irrelevant healthy subject . Participation investigational drug device study within 3 month prior screen . Donation blood 500 mL within three month prior screen . Concomitant disease condition could interfere , treatment might interfere , conduct study , would , opinion Investigator , pose unacceptable risk subject study . Smoker 10 cigarette per day prior screen use tobacco product equivalent 10 cigarette per day . Clinically significant abnormal ECG , judge Investigator . Current infection inflammation study within 1 month prior screen Recent vaccination study within 3 month prior screen . Positive Mantoux test 5 mm . Any confirm significant allergic reaction ( urticaria anaphylaxis ) drug , multiple drug allergy ( nonactive hay fever acceptable ) . Unwillingness inability comply study protocol reason . RMS patient : Previous acute exacerbation , and/or corticosteroid treatment ACTH &lt; 1 month present exacerbation , Hypersensitivity methylprednisolone . Prior use immunosuppressive treatment / diseasemodifying drug ( DMDs ) interferonbeta , glatiramer acetate , fingolimod , dimethylfumarate teriflunomide within 12 month index episode . Shorter period may allow discretion PI approval sponsor . Subjects may continue current therapy interferon , glatiramer acetate , fingolimod , teriflunomide throughout course study . Nonsteroidal antiinflammatory agent , include salicylic acid , avoid administration steroid therapy . If absolutely necessary permit subject treat interferon side effect , patient respond acetaminophen/paracetamol . Current recent ( within 30 day first study treatment ) treatment investigational drug participation investigational study Evidence psychiatric illness History significant cardiac , gastrointestinal , hepatic , pulmonary , renal active immunosuppressive disease . Immune deficiency medical condition would preclude corticosteroid therapy . Any patient pregnant breastfeeding . A urine pregnancy test perform female subject childbearing potential ( define &lt; 2 year last menstruation surgically sterile ) prior start study treatment . For female subject childbearing potential ( define &lt; 2 year last menstruation surgically sterile ) male subject surgically sterile female partner childbearing potential : absence effective , nonhormonal mean contraception ( intrauterine contraceptive device , barrier method contraception conjunction spermicidal gel ) contraindication . Physical examination result laboratory finding may interfere plan treatment , affect patient compliance place patient high risk treatmentrelated complication . Known hypersensitivity cyclodextrin excipients 2B3201 ( e.g . PEG , Cholesterol , HSPC GSH ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>first human</keyword>
	<keyword>2B3-201</keyword>
	<keyword>methylprednisolone</keyword>
	<keyword>CNS-targeting</keyword>
	<keyword>liposomal</keyword>
	<keyword>crossover</keyword>
	<keyword>placebo control</keyword>
	<keyword>active control</keyword>
	<keyword>multiple sclerosis</keyword>
	<keyword>multiple sclerosis relapse</keyword>
</DOC>